{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:04:34Z","timestamp":1789625074379,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02235-8","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:45:23Z","timestamp":1785926723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of GLP-1 and GLP-1\/GIP receptor agonists before, during, and after pregnancy: a narrative review"],"prefix":"10.1186","volume":"18","author":[{"given":"Lenita","family":"Zajdenverg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Masson","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Clara Martins","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Kensy","family":"Previdelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Antonio","family":"Negrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2235_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15620\/cdc\/159281","volume":"508","author":"SD Emmerich","year":"2021","unstructured":"Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023. NCHS Data Brief. 2021;508:1\u20138. https:\/\/doi.org\/10.15620\/cdc\/159281.","journal-title":"NCHS Data Brief"},{"issue":"1","key":"2235_CR2","doi-asserted-by":"publisher","first-page":"e13240","DOI":"10.1111\/mcn.13240","volume":"18","author":"TRB Carrilho","year":"2022","unstructured":"Carrilho TRB, Rasmussen KM, Hutcheon JA, Alves RFS, Farias DR, Freitas-Costa NC, et al. Prevalence and temporal trends in prepregnancy nutritional status and gestational weight gain of adult women followed in the Brazilian Food and Nutrition Surveillance System from 2008 to 2018. Matern Child Nutr. 2022;18(1):e13240\u201313240. https:\/\/doi.org\/10.1111\/mcn.13240.","journal-title":"Matern Child Nutr"},{"issue":"4","key":"2235_CR3","doi-asserted-by":"publisher","first-page":"e2022278","DOI":"10.23750\/abm.v93i4.13466","volume":"93","author":"S Marinelli","year":"2022","unstructured":"Marinelli S, Napoletano G, Straccamore M, Basile G. Female obesity and infertility: outcomes and regulatory guidance. Acta Bio-medica: Atenei Parmensis. 2022;93(4):e2022278\u20132022278. https:\/\/doi.org\/10.23750\/abm.v93i4.13466.","journal-title":"Acta Bio-medica: Atenei Parmensis"},{"issue":"5","key":"2235_CR4","doi-asserted-by":"publisher","first-page":"e0252343","DOI":"10.1371\/journal.pone.0252343","volume":"16","author":"G Hedermann","year":"2021","unstructured":"Hedermann G, Hedley PL, Thagaard IN, Krebs L, Ekelund CK, S\u00f8rensen TIA, et al. Maternal obesity and metabolic disorders associate with congenital heart defects in the offspring: A systematic review. PLoS ONE. 2021;16(5):e0252343\u20130252343. https:\/\/doi.org\/10.1371\/journal.pone.0252343.","journal-title":"PLoS ONE"},{"issue":"11","key":"2235_CR5","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3390\/nu15112420","volume":"15","author":"H Khair","year":"2023","unstructured":"Khair H, Bataineh MF, Zareba K, Alawar S, Maki S, Sallam GS, et al. Pregnant Women\u2019s Perception and Knowledge of the Impact of Obesity on Prenatal Outcomes\u2014A Cross-Sectional Study. Nutrients. 2023;15(11):2420\u20132420. https:\/\/doi.org\/10.3390\/nu15112420.","journal-title":"Nutrients"},{"issue":"2","key":"2235_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/nursrep14020094","volume":"14","author":"WAA AlAnnaz","year":"2024","unstructured":"AlAnnaz WAA, Gouda ADK, Abou El-Soud FA, Alanazi MR. Obesity prevalence and its impact on maternal and neonatal outcomes among pregnant women: a retrospective cross-sectional study design. Nurs Rep. 2024;14(2):1236\u201350. https:\/\/doi.org\/10.3390\/nursrep14020094.","journal-title":"Nurs Rep"},{"key":"2235_CR7","unstructured":"International Diabetes Federation. IDF Diabetes Atlas [Internet]. 11th ed. Brussels, Belgium. 2025. Available from: https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/"},{"issue":"3","key":"2235_CR8","first-page":"151","volume":"14","author":"T Karagiannis","year":"2010","unstructured":"Karagiannis T, Bekiari E, Manolopoulos K, Paletas K, Tsapas A. Gestational diabetes mellitus: why screen and how to diagnose. Hippokratia. 2010;14(3):151\u20134.","journal-title":"Hippokratia"},{"issue":"6","key":"2235_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.20945\/2359-3997000000521","volume":"66","author":"CA Negrato","year":"2022","unstructured":"Negrato CA, Marques PRJ, Leite HB, Torigoe CN, Silva BF, Costa K, et al. Glycemic and nonglycemic mechanisms of congenital malformations in hyperglycemic pregnancies: a narrative review. Arch Endocrinol Metab. 2022;66(6):908\u201318. https:\/\/doi.org\/10.20945\/2359-3997000000521.","journal-title":"Arch Endocrinol Metab"},{"issue":"17","key":"2235_CR10","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.3390\/ijerph191710846","volume":"19","author":"N Malaza","year":"2022","unstructured":"Malaza N, Masete M, Adam S, Dias S, Nyawo T, Pheiffer C. A systematic review to compare adverse pregnancy outcomes in women with pregestational diabetes and gestational diabetes. Int J Environ Res Public Health. 2022;19(17):10846\u201310846. https:\/\/doi.org\/10.3390\/ijerph191710846.","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"2235_CR11","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054.","journal-title":"Gastroenterology"},{"issue":"12","key":"2235_CR12","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1172\/JCI97233","volume":"127","author":"DJ Drucker","year":"2017","unstructured":"Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217\u201327. https:\/\/doi.org\/10.1172\/JCI97233.","journal-title":"J Clin Invest"},{"issue":"3","key":"2235_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153\u201365. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004.","journal-title":"Cell Metab"},{"issue":"6","key":"2235_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metabolism. 2020;31(6):410\u201321. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006.","journal-title":"Trends Endocrinol Metabolism"},{"issue":"10","key":"2235_CR15","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","volume":"66","author":"MA Nauck","year":"2023","unstructured":"Nauck MA, M\u00fcller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66(10):1780\u201395. https:\/\/doi.org\/10.1007\/s00125-023-05956-x.","journal-title":"Diabetologia"},{"issue":"4","key":"2235_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409\u201339. https:\/\/doi.org\/10.1152\/physrev.00034.2006.","journal-title":"Physiol Rev"},{"issue":"10296","key":"2235_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5.","journal-title":"Lancet"},{"issue":"S1","key":"2235_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metabolism. 2018;20(S1):5\u201321. https:\/\/doi.org\/10.1111\/dom.13129.","journal-title":"Diabetes Obes Metabolism"},{"key":"2235_CR19","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:106273","author":"B Stierman","year":"2021","unstructured":"Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, et al. Natl Health Stat Rep. 2021;1581\u201321. https:\/\/doi.org\/10.15620\/cdc:106273. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files-Development of Files and Prevalence Estimates for Selected Health Outcomes."},{"issue":"S1","key":"2235_CR20","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1331\/JAPhA.2009.09078","volume":"49","author":"JJ Neumiller","year":"2009","unstructured":"Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharmacists Association. 2009;49(S1):S16\u201329. https:\/\/doi.org\/10.1331\/JAPhA.2009.09078.","journal-title":"J Am Pharmacists Association"},{"issue":"10","key":"2235_CR21","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","volume":"6","author":"JJ Holst","year":"2024","unstructured":"Holst JJ. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nat Metabolism. 2024;6(10):1866\u201385. https:\/\/doi.org\/10.1038\/s42255-024-01113-9.","journal-title":"Nat Metabolism"},{"key":"2235_CR22","doi-asserted-by":"publisher","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818\u201326. https:\/\/doi.org\/10.1080\/00325481.2015.1090295.","DOI":"10.1080\/00325481.2015.1090295"},{"issue":"10431","key":"2235_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"NCD Risk Factor Collaboration (NCD-RisC), Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies. Lancet. 2024;403(10431):1027\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2.","journal-title":"Lancet"},{"key":"2235_CR24","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metabolism. 2021;46:101102\u2013101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metabolism"},{"issue":"8","key":"2235_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","volume":"39","author":"KA Lyseng-Williamson","year":"2019","unstructured":"Lyseng-Williamson KA. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. Clin Drug Investig. 2019;39(8):805\u201319. https:\/\/doi.org\/10.1007\/s40261-019-00826-0.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"2235_CR26","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","volume":"66","author":"M Tsch\u00f6p","year":"2023","unstructured":"Tsch\u00f6p M, Nogueiras R, Ahr\u00e9n B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66(10):1796\u2013808. https:\/\/doi.org\/10.1007\/s00125-023-05929-0.","journal-title":"Diabetologia"},{"key":"2235_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292\u20131431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292.","journal-title":"Front Endocrinol"},{"issue":"3","key":"2235_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s42000-018-0038-0","volume":"17","author":"D Sfairopoulos","year":"2018","unstructured":"Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones. 2018;17(3):333\u201350. https:\/\/doi.org\/10.1007\/s42000-018-0038-0.","journal-title":"Hormones"},{"issue":"12","key":"2235_CR29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/biom12121736","volume":"12","author":"D Khan","year":"2022","unstructured":"Khan D, Ojo OO, Woodward ORM, Lewis JE, Sridhar A, Gribble FM, et al. Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. Biomolecules. 2022;12(12):1736\u20131736. https:\/\/doi.org\/10.3390\/biom12121736.","journal-title":"Biomolecules"},{"issue":"2","key":"2235_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","volume":"184","author":"CE Cesta","year":"2024","unstructured":"Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024;184(2):144\u201352. https:\/\/doi.org\/10.1001\/jamainternmed.2023.6663.","journal-title":"JAMA Intern Med"},{"key":"2235_CR31","doi-asserted-by":"publisher","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","volume":"14","author":"DRP Muller","year":"2023","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol. 2023;14:1215356\u20131215356. https:\/\/doi.org\/10.3389\/fendo.2023.1215356.","journal-title":"Front Endocrinol"},{"issue":"18","key":"2235_CR32","doi-asserted-by":"publisher","first-page":"10361","DOI":"10.3390\/ijms231810361","volume":"23","author":"AM Krasnyi","year":"2022","unstructured":"Krasnyi AM, Sadekova AA, Smolnova TY, Chursin VV, Buralkina NA, Chuprynin VD, et al. The Levels of Ghrelin, Glucagon, Visfatin and GLP-1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis along with the Increased Expression of the CD10 Protease by the Macrophages. Int J Mol Sci. 2022;23(18):10361\u201310361. https:\/\/doi.org\/10.3390\/ijms231810361.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2235_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/09513590.2014.975686","volume":"31","author":"B Artunc-Ulkumen","year":"2015","unstructured":"Artunc-Ulkumen B, Pala HG, Pala EE, Yavasoglu A, Yigitturk G, Erbas O. Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecol Endocrinol. 2015;31(3):196\u2013201. https:\/\/doi.org\/10.3109\/09513590.2014.975686.","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"2235_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/AOG.0000000000005825","volume":"145","author":"J Finkle","year":"2025","unstructured":"Finkle J, Brost BC. Role of glucagon-like peptide-1 receptor agonists in people with infertility and pregnancy. Obstet Gynecol. 2025;145(3):286\u201396. https:\/\/doi.org\/10.1097\/AOG.0000000000005825.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2235_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14656566.2022.2108702","volume":"24","author":"N Helvaci","year":"2023","unstructured":"Helvaci N, Yildiz BO. Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert Opin Pharmacother. 2023;24(1):105\u201320. https:\/\/doi.org\/10.1080\/14656566.2022.2108702.","journal-title":"Expert Opin Pharmacother"},{"key":"2235_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13093","author":"CR McCartney","year":"2022","unstructured":"McCartney CR, Campbell RE, Marshall JC, Moenter SM. The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome. J Neuroendocrinol. 2022. https:\/\/doi.org\/10.1111\/jne.13093.","journal-title":"J Neuroendocrinol"},{"key":"2235_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251383064","author":"BH Hoteit","year":"2025","unstructured":"Hoteit BH, Kotaich J, Ftouni H, Hazime F, Safawi A, Masri R, et al. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. Ther Adv Endocrinol Metab. 2025. https:\/\/doi.org\/10.1177\/20420188251383064.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"2235_CR38","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng S, Lin R, Xie Y, Chen H, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol. 2017;87(6):767\u201374. https:\/\/doi.org\/10.1111\/cen.13454.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2235_CR39","doi-asserted-by":"publisher","first-page":"16512","DOI":"10.1038\/s41598-025-99622-4","volume":"15","author":"S Lin","year":"2025","unstructured":"Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025;15(1):16512\u201316512. https:\/\/doi.org\/10.1038\/s41598-025-99622-4.","journal-title":"Sci Rep"},{"issue":"1","key":"2235_CR40","doi-asserted-by":"publisher","first-page":"e15474","DOI":"10.1111\/dme.15474","volume":"42","author":"S Gunabalasingam","year":"2025","unstructured":"Gunabalasingam S, Kyrka A, Hopkins L, Lebrett R, Dyer E, Forde R, et al. Interventions in women with type 2 diabetes mellitus in the pre-pregnancy, pregnancy and postpartum periods to optimise care and health outcomes: A systematic review. Diabet Med. 2025;42(1):e15474\u201315474. https:\/\/doi.org\/10.1111\/dme.15474.","journal-title":"Diabet Med"},{"key":"2235_CR41","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.2147\/DDDT.S506957","volume":"19","author":"JS Min","year":"2025","unstructured":"Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, et al. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1\/GIP Receptor Agonist. Drug Des Devel Ther. 2025;19:3509\u201337. https:\/\/doi.org\/10.2147\/DDDT.S506957.","journal-title":"Drug Des Devel Ther"},{"key":"2235_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6904-12-8","volume":"12","author":"PA Kothare","year":"2012","unstructured":"Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women. BMC Clin Pharmacol. 2012;12:8\u20138. https:\/\/doi.org\/10.1186\/1472-6904-12-8.","journal-title":"BMC Clin Pharmacol"},{"key":"2235_CR43","unstructured":"Eli, Lilly. Company. A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/show\/NCT04172987"},{"issue":"1","key":"2235_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.japh.2023.10.037","volume":"64","author":"JW Skelley","year":"2024","unstructured":"Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003). 2024;64(1):204\u201311. https:\/\/doi.org\/10.1016\/j.japh.2023.10.037.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"2235_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14831","volume":"25","author":"C De Block","year":"2023","unstructured":"De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab. 2023;25(1):3\u201317. https:\/\/doi.org\/10.1111\/dom.14831.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2235_CR46","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.clinme.2025.100298","volume":"25","author":"MS Varughese","year":"2025","unstructured":"Varughese MS, O\u2019Mahony F, Varadhan L. GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence. Clin Med. 2025;25(2):100298\u2013100298. https:\/\/doi.org\/10.1016\/j.clinme.2025.100298.","journal-title":"Clin Med"},{"issue":"5","key":"2235_CR47","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00404-024-07849-9","volume":"311","author":"SAL Price","year":"2025","unstructured":"Price SAL, Nankervis A. Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review. Arch Gynecol Obstet. 2025;311(5):1241\u20137. https:\/\/doi.org\/10.1007\/s00404-024-07849-9.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"2235_CR48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/bcp.16354","volume":"91","author":"J Zhou","year":"2025","unstructured":"Zhou J, Wei Z, Lai W, Liu M, Wu X. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: a pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2025;91(4):1272\u201380. https:\/\/doi.org\/10.1111\/bcp.16354.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2235_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1191\/0960327103ht402oa","volume":"22","author":"RA Hiles","year":"2003","unstructured":"Hiles RA, Bawdon RE, Petrella EM. Ex vivo human placental transfer of the peptides pramlintide and exenatide. Hum Exp Toxicol. 2003;22(12):623\u20138. https:\/\/doi.org\/10.1191\/0960327103ht402oa.","journal-title":"Hum Exp Toxicol"},{"issue":"3\u20134","key":"2235_CR50","first-page":"70","volume":"27","author":"M Ivani\u0161evi\u0107","year":"2018","unstructured":"Ivani\u0161evi\u0107 M, Herman M, Horvati\u010dek M, Vu\u010di\u0107 Lovren\u010di\u0107 M, elmi\u0161 J. Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report. Gynaecologia et Perinatologia. 2018;27(3\u20134):70\u20132.","journal-title":"Gynaecologia et Perinatologia"},{"issue":"10","key":"2235_CR51","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","volume":"24","author":"\u015eE Do\u011fan","year":"2024","unstructured":"Do\u011fan \u015eE, Ku\u015fkonmaz \u015eM, Koc G, Aypar E, \u00c7ulha C. Case Series: Exposure to Glucagon-like Peptide-1 Receptor Agonist in the First Trimester of Pregnancy in Two Siblings. Endocr Metab Immune Disord Drug Targets. 2024;24(10):1237\u20139. doi:10.2174\/0118715303252109231023115112 PubMed PMID: 37937565.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2235_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjcard.2025.03.013","volume":"246","author":"M Hanif","year":"2025","unstructured":"Hanif M, Hays AG, Nagarajan JS, Sah SP, Weinstock RS, Taub CC. Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes. Am J Cardiol. 2025;246:10\u20133. https:\/\/doi.org\/10.1016\/j.amjcard.2025.03.013.","journal-title":"Am J Cardiol"},{"key":"2235_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083550","author":"K Dao","year":"2024","unstructured":"Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services. BMJ Open. 2024. https:\/\/doi.org\/10.1136\/bmjopen-2023-083550.","journal-title":"BMJ Open"},{"key":"2235_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01291","volume":"9","author":"V Garcia-Flores","year":"2018","unstructured":"Garcia-Flores V, Romero R, Miller D, Xu Y, Done B, Veerapaneni C, et al. Inflammation-induced adverse pregnancy and neonatal outcomes can be improved by the immunomodulatory peptide exendin-4. Front Immunol. 2018;9:1291\u20131291. https:\/\/doi.org\/10.3389\/fimmu.2018.01291.","journal-title":"Front Immunol"},{"issue":"2","key":"2235_CR55","doi-asserted-by":"publisher","first-page":"116.e1","DOI":"10.1016\/j.ajog.2025.01.019","volume":"233","author":"MR Imbroane","year":"2025","unstructured":"Imbroane MR, LeMoine F, Nau CT. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am J Obstet Gynecol. 2025;233(2):116.e1-116.e7. https:\/\/doi.org\/10.1016\/j.ajog.2025.01.019.","journal-title":"Am J Obstet Gynecol"},{"issue":"24","key":"2235_CR56","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1001\/jama.2025.20951","volume":"334","author":"J Maya","year":"2025","unstructured":"Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, et al. Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA. 2025;334(24):2186\u201396. https:\/\/doi.org\/10.1001\/jama.2025.20951.","journal-title":"JAMA"},{"issue":"5","key":"2235_CR57","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1111\/dom.70615","volume":"28","author":"R Scairati","year":"2026","unstructured":"Scairati R, Newman C, Dunne FP, Colao A. Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation. Diabetes Obes Metab. 2026;28(5):3462\u20134. https:\/\/doi.org\/10.1111\/dom.70615 . PubMed PMID: 41749408; PubMed Central PMCID: PMC13071202.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2235_CR58","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11606-025-09950-4","volume":"41","author":"L Zhou","year":"2026","unstructured":"Zhou L, Wei A, Pan C, Zhang J, Hu P, Li X, et al. Effects of glucagon-like peptide-1 receptor agonists after treatment withdrawal: a systematic review and meta-analysis. J Gen Intern Med. 2026;41(3):807\u201318. https:\/\/doi.org\/10.1007\/s11606-025-09950-4.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2235_CR59","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","volume":"122","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344\u201367. https:\/\/doi.org\/10.1016\/j.ajcnut.2025.04.023 . PubMed PMID: 40450457.","journal-title":"Am J Clin Nutr"},{"issue":"Supplement1","key":"2235_CR60","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.2337\/dc26-S015","volume":"49","author":"M Bajaj","year":"2026","unstructured":"Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, Bennett AK, et al. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes\u20142026. Diabetes Care. 2026;49(Supplement1):S321\u201338. https:\/\/doi.org\/10.2337\/dc26-S015.","journal-title":"Diabetes Care"},{"key":"2235_CR61","doi-asserted-by":"publisher","unstructured":"Zajdenverg L, Dualib PM, Fa\u00e7anha CF, Golbert A, Negrato CA, Forti AC et al. e,. Tratamento farmacol\u00f3gico do diabetes na gesta\u00e7\u00e3o. In: Diretriz Oficial da Sociedade Brasileira de Diabetes. Conectando Pessoas; 2023. https:\/\/doi.org\/10.29327\/557753.2022-13","DOI":"10.29327\/557753.2022-13"},{"issue":"9","key":"2235_CR62","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/jcm10091891","volume":"10","author":"M Makama","year":"2021","unstructured":"Makama M, Skouteris H, Moran LJ, Lim S. Reducing Postpartum Weight Retention. J Clin Med. 2021;10(9):1891\u20131891. https:\/\/doi.org\/10.3390\/jcm10091891.","journal-title":"J Clin Med"},{"issue":"24","key":"2235_CR63","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/jama.2025.20947","volume":"334","author":"M Bliddal","year":"2025","unstructured":"Bliddal M, Nohmie G, Damkier P, Potteg\u00e5rd A. Increasing postpartum use of GLP-1 receptor agonists. JAMA. 2025;334(24):2227\u20139. https:\/\/doi.org\/10.1001\/jama.2025.20947.","journal-title":"JAMA"},{"key":"2235_CR64","unstructured":"European Medicines Agency. Ozempic: Summary of Product Characteristics [Internet]. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"2235_CR65","unstructured":"National Institute of Child Health, Development H. Semaglutide. Drugs and Lactation Database (LactMed) [Internet]. 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544016\/"},{"key":"2235_CR66","unstructured":"National Institute of Child Health, Development H. Tirzepatide. Drugs and Lactation Database (LactMed) [Internet]. 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK581488\/"},{"issue":"17","key":"2235_CR67","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.3390\/nu16172886","volume":"16","author":"H Diab","year":"2024","unstructured":"Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024;16(17):2886\u20132886. https:\/\/doi.org\/10.3390\/nu16172886.","journal-title":"Nutrients"},{"key":"2235_CR68","doi-asserted-by":"publisher","unstructured":"Thompson J, Diab H, Datta P, Krutsch K. Tirzepatide (Zepbound) in Human Milk During Periods of Maternal Dosing [Internet]. 2025 Jan. https:\/\/doi.org\/10.2139\/ssrn.5387250","DOI":"10.2139\/ssrn.5387250"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02235-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:47:32Z","timestamp":1789624052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02235-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02235-8","relation":{"references":[{"id-type":"doi","id":"10.15620\/cdc:106273","asserted-by":"subject"}]},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"205"}}